Increasing access to cancer trials in Minnesota (InACT-MN)

增加明尼苏达州癌症试验的机会 (InACT-MN)

• 批准号: 10636408
• 负责人: Britt Kristina Erickson
• 金额: $ 18.28万
• 依托单位: UNIVERSITY OF MINNESOTA
• 依托单位国家: 美国
• 财政年份: 2023
• 资助国家: 美国
• 起止时间: 2023-09-18 至 2028-08-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10636408
• 关键词: Area; Body of uterus; Cancer Burden; Cancer Center; Cancer Control; Cause of Death; Clinical; Clinical Trials; Clinical Trials Design; Clinical Trials Network; Collaborations; Communities; Community Medicine; Development; Disease; ERBB2 gene; Endometrial Carcinoma; Enrollment; Exemestane; Funding; Gynecologic Oncology; Health; Improve Access; Infrastructure; Knowledge; Leadership; Location; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Mentors; Minnesota; Mission; Native Americans; Oncologist; Oncology; Patients; Phase; Population; Prevention trial; Principal Investigator; Process; Protocols documentation; Research; Review Committee; Role; Rural; Services; Site; Specialist; Therapeutic Clinical Trial; Therapeutic Trials; Treatment outcome; Universities; University of Minnesota Cancer Center; Vision; Work; cancer clinical trial; cancer health disparity; cancer prevention; experience; health care delivery; improved; innovation; member; mentoring community; metropolitan; novel; public health relevance; service delivery; skills; success

PROJECT SUMMARY/ABSTRACT In collaboration with the Masonic Cancer Center of the University of Minnesota, Britt Erickson, MD, has developed a research strategy that will leverage her skills in clinical trial design and execution, as well as her experience as a mentor and educator, to improve access to NCI clinical trials within the Masonic Cancer Center and throughout greater Minnesota. She will open and enroll to more NCI prevention and therapeutic trials in gynecologic oncology. She will collaborate with other disease site leaders and cooperative group principal investigators in order to prioritize trials with the highest chances for success at the University of Minnesota. She will be the community clinical trial liaison for the Masonic Cancer Center, opening gynecologic oncology specific NCI trials at community sites and mentoring community oncologists in the process of clinical trial leadership and accrual. This community extension will be done through the M Health Fairview Cancer Service Line, a novel clinical entity established in 2019 as a result of combining efforts between the University of Minnesota and Fairview, a non- profit healthcare delivery service. The M Health Fairview Cancer Service Line includes seven community sites throughout the Minneapolis/St Paul metropolitan area and presents an opportunity to break down traditional barriers between academic and community medicine, uniting with a common vision of increasing access to therapeutic clinical trials. The Cancer Service Line has also extended to two underserved sites in rural central Minnesota with a substantial Native American population and historically limited clinical trial access. At these locations—working with community oncologists, existing NCORP infrastructure, and pre-existing collaborations through the Minnesota Cancer Clinical Trials Network (a state funded network since 2017, housed at the University of Minnesota)—Dr. Erickson will be integral to the mission of expanding NCI clinical trial access to all Minnesotans. Dr. Erickson’s experience and current involvement locally and nationally in NCI clinical trial work make her an ideal candidate for the proposed plan. In addition to expanding trial availability, she will continue her local and national service. This includes serving as a member of the Cancer Protocol Review Committee and as co-chair of the Gynecologic Oncology Interdisciplinary Site Committee within the Masonic Cancer Center. It also involves serving as a core member of the Uterine Corpus Committee and Cancer Prevention and Control Committee of NRG oncology. She will also continue her work as the national PI of the phase II DCP trial of exemestane in endometrial cancer (UWI-2016-08-01) and national PI of a new cooperative group study, NRG- GY026, which is exploring the role of HER2 directed therapy in HER2 positive endometrial cancer, set to open in June of 2022 with planned accrual of 525 patients.

项目概要/摘要 医学博士 Britt Erickson 与明尼苏达大学共济会癌症中心合作， 制定了一项研究策略，该策略将利用她在临床试验设计和执行方面的技能，以及她的 作为导师和教育者的经验，以改善共济会癌症中心内 NCI 临床试验的机会 整个明尼苏达州和大明尼苏达州的中心。 她将开放并招募更多妇科肿瘤学 NCI 预防和治疗试验。 与其他疾病现场领导和合作小组主要研究人员合作，以确定优先顺序 她将在明尼苏达大学进行社区临床试验，成功机会最高。 共济会癌症中心的试验联络员，在社区开展妇科肿瘤特定 NCI 试验 站点并在临床试验领导和应计过程中指导社区肿瘤学家。 社区扩展将通过 M Health Fairview 癌症服务热线（一个新型临床实体）完成 Fairview 成立于 2019 年，是明尼苏达大学和 Fairview（非 M Health Fairview 癌症服务热线包括七个社区站点。 整个明尼阿波利斯/圣保罗都市区，提供了一个打破传统的机会 学术和社区医学之间的障碍，结合增加获得机会的共同愿景 癌症服务热线还延伸至农村中心的两个服务不足的地点。 明尼苏达州拥有大量美洲原住民人口，历史上临床试验机会有限。 地点——与社区肿瘤学家、现有的 NCORP 基础设施以及预先存在的合作合作 通过明尼苏达州癌症临床试验网络（自 2017 年起由国家资助的网络，位于 明尼苏达大学）—Erickson 博士将成为扩大 NCI 临床试验覆盖范围的使命中不可或缺的一部分。 所有明尼苏达人。 Erickson 博士的经验以及目前在本地和全国范围内参与 NCI 临床试验工作的经历使她成为 除了扩大试验范围外，她还将继续在当地和地区开展工作。 这包括担任癌症方案审查委员会的成员和联合主席。 共济会癌症中心妇科肿瘤学跨学科站点委员会的成员。 担任子宫体委员会及癌症防治委员会核心成员 她还将继续担任 NRG 肿瘤学委员会 II 期 DCP 试验的国家 PI。 依西美坦治疗子宫内膜癌 (UWI-2016-08-01) 和一项新合作小组研究 NRG- 的国家 PI 正在探索 HER2 定向治疗在 HER2 阳性子宫内膜癌中的作用的 GY026 即将开放 到 2022 年 6 月，计划招募 525 名患者。